A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Recruiting · Phase 4 · NCT06857942
Conditions: Psoriasis, Overweight or Obesity
At a glance
- Research payments reported, 2025
- $6,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug)
- Dates
- Started 2025-03-19; completion 2028-05
- Results posted
- Not yet
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $6,500 in research payments for this study in 2025 (1 payments).
Products named: Taltz
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Bukhalo Michael MD $6,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.